Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/243—Platinum; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to the treatment of cancers and more particularly to the use of cis-rhenium (III) diadamantate compounds for potentiating the antitumoral activity of cytotoxic platinum complexes.
• the present invention also relates to novel pharmaceutical associations comprising as active principles a cytotoxic platinum complex and a cis-rhenium (III) diadamatate compound.
• the two above active principles may be associated in a single pharmaceutical composition with a pharmaceutically acceptable vehicule.
• each active principle may be also conditioned separately in order to allow their sequential administration.
• each active principle is preferably in combination with a pharmaceutically acceptable vehicule.
• the main platinum complexes known as cytotoxic agents are the cisplatin, carboplatin, oxaliplatin and nedaplatin. Regarding the antitumoral activity of these platinum complexes, the following references may be cited:
• Rhenium Carboxylates as Antitumor Agents. Part II. Antitumor Studies of Rhenium Carboxylates.
• the cluster rhenium compounds useful according to the invention are the compounds of formula (I):
• X is chlorine or bromine; R is the residue of adamantanecarboxylic acid; - L is H 2 O; CH 3 CN, DMPA, DMAA, DMSO or pyridine.
• DMPA dimethylphosphamide
• DMAA dimethylacetamide
• the preferred compound among the above compounds is the compound of formula: cis [Re 2 (AdCOO) 2 CL 4 ] ⁇ CH 3 CN in which AdCOO is the residue of adamantanecarboxylic acid.
• the present invention also relates to the use of the cluster rhenium compounds of formula (I) for the preparation of medicaments useful for potentiation of the antitumoral activity of platinum complexes.
• the present invention also relates to the use of the cluster rhenium compounds of formula (I) in association with cytotoxic platinum complexes for the preparation of antitumoral agents.
• the amount of rhenium coumpounds of formula (I) to be used depends on the tumors to be treated and the state of the patient. Generally the dose to be used may vary between 1 and 10O mg per kg of the body of the patient to be treated.
• Wistar rats weighting 100-120 g were inoculated by tumor carcinoma Guerink (T8) cells (Experimental Oncology, 2003, Vol. 25, pp64-68). The cells were taken in the Institute of Oncology and Experimental Pathology by R.E.Kavetskiy (Kiev).
• the single intraperitoneal administration of Cisplatin at the dose of 8 mg/kg was made on the 9 day after the tumor inoculation according to the method disclosed by Taylor S. K. in Medical Hypothesis 2003; 60; n°1, pp 89-93.
• Weight of isolated tumors and Hb levels in average were the same as in control group as in group treated by Re2 (Table 1 ).
• Table 1 Weight of isolated tumors (m, g) and concentration of Hb (Hb, g/l) in blood of animals on the 21 day after tumor cells inoculation

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37387389

Family Applications (1)

Country Status (4)

• 2006
  • 2006-05-19 EP EP06300497A patent/EP1862169A1/de not_active Withdrawn
• 2007
  • 2007-05-18 EP EP07729273A patent/EP2068894B1/de not_active Not-in-force
  • 2007-05-18 WO PCT/EP2007/054828 patent/WO2007135095A1/en active Application Filing
  • 2007-05-18 DE DE602007007970T patent/DE602007007970D1/de active Active
  • 2007-05-18 AT AT07729273T patent/ATE474584T1/de not_active IP Right Cessation

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events